What Happens in the Brain During Psychedelic Therapy

Psilocybin reduces activity in the Default Mode Network (DMN), the brain network associated with self-referential thinking, rumination, and rigid mental patterns. A 2012 study published in PNAS by Carhart-Harris et al. found that this suppression of DMN activity correlates with the subjective experience of ego dissolution and broader emotional perspective.

Simultaneously, psilocybin increases connectivity between brain regions that do not normally communicate, producing what researchers describe as a more fluid and integrated brain state. This temporary shift in neural activity is the proposed mechanism behind therapeutic gains in depression and anxiety.

The Role of Set and Setting

Set and setting refers to the principle that mindset (set) and physical environment (setting) are primary determinants of the psychedelic experience. In clinical protocols, both are carefully controlled: patients undergo preparatory sessions, and the therapy room is designed to feel calm, supportive, and free of interruption.

Guides or therapists remain present throughout the session to provide reassurance and reduce the risk of anxiety or psychological distress.

Integration: The Work After the Session

Integration is the structured process of reviewing, discussing, and applying insights gained during a psilocybin session. Most clinical protocols include multiple post-session integration meetings with a therapist to help patients make sense of their experience.

Integration may include journaling, talk therapy, and lifestyle reflection. Research suggests that participants who engage in post-session integration report more durable improvements than those who do not.

What Research Is Still Investigating

Psychedelic-assisted therapy remains an active area of clinical investigation, with large-scale trials underway to establish dosing protocols, long-term outcomes, and patient selection criteria. Current open questions include:

• Long-term therapeutic durability beyond 12 months
• Optimal number of sessions and dose frequency
• Which conditions and patient profiles respond best
• How outcomes compare to existing first-line treatments

Why Psychedelic Therapy Requires Professional Oversight

Psychedelic therapy is a structured clinical intervention, not a self-guided process. Screening for contraindications, supervised dosing, and post-session support are all required components in established trial protocols.

Unsupervised use carries a higher risk of psychological distress, particularly for individuals with a personal or family history of psychosis or bipolar disorder, who are typically excluded from clinical trials for this reason.

Key Takeaways from Part 2

The therapeutic potential of psilocybin is inseparable from the structure around it. The neurological mechanism, the clinical environment, and the integration process each contribute independently to outcomes. Understanding this context clarifies why supervised psychedelic therapy is categorically different from unsupervised use.

Learn More About Psilocybin

For those interested in learning more about psilocybin outside of clinical research, educational resources and products are available through the Canadian market.

Explore Psilocybin Products